The primary objective of this study is to test whether vaccinating LTCF residents ≥65 years with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine as compared to control (PCV13) leads to an increase in detectable neutralizing antibodies. Participants will be randomized to receive either the Pfizer COVID-19 vaccine or the Pnemoccocal Prevnar-13 vaccine at baseline after bloodwork is drawn. Another blood sample will be taken 28 days later. After completion of the study, participants in the control group (pneumococcal Prevnar-13 vaccine) will be given a fourth dose of mRNA COVID-19 vaccine and will have their blood drawn 28 days post-vaccination.
Age
65–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
LTCF residents ≥ 65 years who have received three doses of mRNA vaccine.
You may not be if
Immunocompromised individuals due to known or suspected immunodeficiency or due to receipt of immunosuppressive medication (e.g., steroids, biologics).
Having had a severe adverse reaction (e.g., anaphylactic allergy) to mRNA or pneumococcal vaccine.
Having received pneumococcal polysaccharide vaccine within 12 months.
LTCF residents who have an interval less than 3 months from their third mRNA COVID vaccine dose.
Clareo Health | Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs
